ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

The European Society for Medical Oncology (ESMO) held a virtual consensus-building process on epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer in 2021. The consensus included a multidisciplinary panel of 34 leading experts in the management of lung cancer. The aim of the con...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of oncology Jg. 33; H. 5; S. 466
Hauptverfasser: Passaro, A, Leighl, N, Blackhall, F, Popat, S, Kerr, K, Ahn, M J, Arcila, M E, Arrieta, O, Planchard, D, de Marinis, F, Dingemans, A M, Dziadziuszko, R, Faivre-Finn, C, Feldman, J, Felip, E, Curigliano, G, Herbst, R, Jänne, P A, John, T, Mitsudomi, T, Mok, T, Normanno, N, Paz-Ares, L, Ramalingam, S, Sequist, L, Vansteenkiste, J, Wistuba, I I, Wolf, J, Wu, Y L, Yang, S R, Yang, J C H, Yatabe, Y, Pentheroudakis, G, Peters, S
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England 01.05.2022
Schlagworte:
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Consensus
ErbB Receptors - genetics
Humans
Lung Neoplasms - genetics
Lung Neoplasms - therapy
Medical Oncology
consensus
lung cancer
targeted therapy
treatment
EGFR
testing
ISSN:1569-8041, 1569-8041
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The European Society for Medical Oncology (ESMO) held a virtual consensus-building process on epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer in 2021. The consensus included a multidisciplinary panel of 34 leading experts in the management of lung cancer. The aim of the consensus was to develop recommendations on topics that are not covered in detail in the current ESMO Clinical Practice Guideline and where the available evidence is either limited or conflicting. The main topics identified for discussion were: (i) tissue and biomarkers analyses; (ii) early and locally advanced disease; (iii) metastatic disease and (iv) clinical trial design, patient's perspective and miscellaneous. The expert panel was divided into four working groups to address questions relating to one of the four topics outlined above. Relevant scientific literature was reviewed in advance. Recommendations were developed by the working groups and then presented to the entire panel for further discussion and amendment before voting. This manuscript presents the recommendations developed, including findings from the expert panel discussions, consensus recommendations and a summary of evidence supporting each recommendation.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Instructional Material/Guideline-3
content type line 23
ISSN:1569-8041
1569-8041
DOI:10.1016/j.annonc.2022.02.003